Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
02 03 2022
Historique:
received: 26 02 2021
accepted: 03 06 2021
pubmed: 19 6 2021
medline: 15 3 2022
entrez: 18 6 2021
Statut: ppublish

Résumé

To describe disease presentation and long-term outcome of granulomatosis with polyangiitis (GPA) patients according to blood eosinophils count (Eos) at vasculitis diagnosis. Data from newly diagnosed GPA patients registered in the French Vasculitis Study Group database with available eosinophil count at diagnosis were reviewed. Disease characteristics, rate and type of relapses, and overall survival were analysed according to Eos, categorized as normal (<500/mm3), mild-to-moderate hypereosinophilia (HE) (between 500 and 1500/mm3) and severe HE (>1500/mm3). Three hundred and fifty-four patients were included. At diagnosis, 90 (25.4%) patients had HE ≥500/mm3; they were more likely male (73% vs 56%, P = 0.006) and had more frequent cutaneous manifestations (49% vs 33%, P = 0.01), peripheral neuropathy (32% vs 17%, P = 0.004) and higher BVAS (21 vs 18, P = 0.01), compared with those with Eos <500/mm3. Patients with severe HE (n = 28; median Eos 2355, range 1500-9114) had more frequent renal function worsening at presentation (P = 0.008). After a median follow-up of 3.95 (interquartile range 1.95-6.76) years, no difference was found in overall relapse rates according to baseline Eos, but those with HE experienced more neurological (P = 0.013) and skin (P = 0.024) relapses and had more frequently peripheral neuropathy as damage at last follow-up (P = 0.02). Overall survival was not significantly different in patients with normal Eos or HE at diagnosis. (P = 0.08). Blood HE at diagnosis, observed in about one-quarter of GPA patients, identifies a subgroup of patients with a more severe disease and higher rate of skin and neurological involvement both at presentation and during follow-up.

Identifiants

pubmed: 34142135
pii: 6303624
doi: 10.1093/rheumatology/keab495
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1211-1216

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Michele Iudici (M)

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Rheumatology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Xavier Puéchal (X)

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Christian Pagnoux (C)

Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, Canada.

Delphine S Courvoisier (DS)

Rheumatology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Mohamed Hamidou (M)

Centre Hospitalier Universitaire Hôtel-Dieu, Nantes.

Claire Blanchard-Delaunay (C)

Service de Médecine Interne, Centre Hospitalier de Niort, Niort.

François Maurier (F)

Service de Médecine Interne, Groupe Hospitalier UNEOS, Metz-Vantoux.

Marc Ruivard (M)

Service de Médecine Interne, CHU, Clermont-Ferrand.

Thomas Quéméneur (T)

Département de Médecine Interne, Centre Hospitalier, Valenciennes.

Olivier Aumaître (O)

Service de Médecine Interne, CHU, Clermont-Ferrand.

Loïc Guillevin (L)

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Hôpital Cochin, Université de Paris, Paris, France.

Benjamin Terrier (B)

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Hôpital Cochin, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH